Efficacy and safety of lixisenatide in comparison to placebo: a meta-analysis of randomized controlled trials

Abstract

Abstract: AIM: To estimate the efficacy and tolerability of lixisenatide in comparison to placebo in the treatment of type 2 diabetes.METHODS: PubMed, EMBASE, OVID, Cochrane, CNKI, VIP, CBM were searched and randomized controlled trials (RCT) of lixisenatide vs. placebo in treating type 2 diabetes were collected. The quality of included randomized controlled trials (RCTs) was assessed and then analyzed by the software RevMan5.2. The potential publication bias was performed by Stata 12.0 soft. Sensitivity analyses were used in the treatment course.RESULTS: Eight RCTs were ultimately identified. The results of meta-analyses showed that the proportion of patients that achieved an HbA1c ＜7%or≤6.5% was significantly greater in lixisenatide group than that in placebo group, there was statistical significance. The number of total adverse events, hypoglycemia, injection sites reactions, gastrointestinal disorders, nausea, vomiting, dizziness events in lixisenatide group was significantly lower than that in control group, there was statistical significance. Most of the adverse events reported were mild to moderate in intensity.CONCLUSION: The results of meta-analyses indicate that lixisenatide treatment for type 2 diabetes is effective. The major adverse of lixisenatide were hypoglycemia, injection site reactions, gastrointestinal disorders, nausea, vomiting, dizziness, headache, diarrhea. Although it may increase the risk of the adverse events,which reported were mild to moderate in intensity, lixisenatide appears to be an effective treatment for type 2 diabetes and a long-term study in large scale with high quality is required to confirm its long-term outcomes.

Key words: lixisenatide, type 2 diabetes, randomized controlled trials, Meta-analysis

CLC Number:

R311

WU Yan, WU Cui-fang, WANG Jiang-lin. Efficacy and safety of lixisenatide in comparison to placebo: a meta-analysis of randomized controlled trials[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(2): 167-174.

References

[1] American Diabetes Association.Standards of medical care in diabetes--2013[J].Diabetes Care, 2013, 36 Suppl 1: S11-S66.
[2] Alvarez GF, Mavros P, Nocea G,et al.Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study[J].Diabetes Obes Metab, 2008, 10 Suppl 1: 8-15.
[3] Nathan DM, Buse JB, Davidson MB,et al.Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes[J].Diabetes Care, 2009, 32(1): 193-203.
[4] Rodbard HW, Jellinger PS, Davidson JA,et al.Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control[J].Endocr Pract, 2009, 15(6): 540-559.
[5] Tews D, Werner U, Eckel J.Enhanced protection against cytokine- and fatty acid-induced apoptosis in pancreatic beta cells by combined treatment with glucagon-like peptide-1 receptor agonists and insulin analogues[J].Horm Metab Res, 2008, 40(3): 172-180.
[6] Werner U, Vandewalle B, Conte JK,et al.The GLP-1 receptor agonist AVE0010 improves GSIS, prevents lipotoxicity-induced insulin depletion and preserves beta-cell function in human pancreatic islets[J].Diabetes, 2008, 571: A3-A4.
[7] Haschke G, Haag-Diergarten S, Werner U,et al.The GLP-1 receptor agonist AVE0010 preserves beta cell function and insulin secretion after a 6 week treatment in male obese Zucker diabetic fatty rats - an isolated perfused pancreas study[J].Diabetologia, 2006, 491: 400-401.
[8] Thorkildsen C, Neve S, Larsen BD,et al.Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice[J].J Pharmacol Exp Ther, 2003, 307(2): 490-496.
[9] Moore MC, Werner U, Smith MS,et al.Effect of the glucagon-like peptide-1 receptor agonist lixisenatide on postprandial hepatic glucose metabolism in the conscious dog[J].Am J Physiol Endocrinol Metab, 2013,305(12):1473-1482.
[10]Elkinson S, Keating GM.Lixisenatide: first global approval[J].Drugs, 2013, 73(4): 383-391.
[11]Bolli GB, Munteanu M, Dotsenko S,et al.Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1)[J].Diabet Med, 2014,31(2):176-184.
[12]Ahren B, Leguizamo DA, Miossec P,et al.Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M)[J].Diabetes Care, 2013, 36(9): 2543-2550.
[13]Fonseca VA, Alvarado-Ruiz R, Raccah D,et al.Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)[J].Diabetes Care, 2012, 35(6): 1225-1231.
[14]Pinget M, Goldenberg R, Niemoeller E,et al.Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P)[J].Diabetes Obes Metab, 2013, 15(11): 1000-1007.
[15]Ratner RE, Rosenstock J, Boka G.Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial[J].Diabet Med, 2010, 27(9): 1024-1032.
[16]Riddle MC, Aronson R, Home P,et al.Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L)[J].Diabetes Care, 2013, 36(9): 2489-2496.
[17]Riddle MC, Forst T, Aronson R,et al.Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1)[J].Diabetes Care, 2013, 36(9): 2497-2503.
[18]Seino Y, Min KW, Niemoeller E,et al.Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)[J].Diabetes Obes Metab, 2012, 14(10): 910-917.
[19]Werner U, Haschke G, Herling AW,et al.Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes[J].Regul Pept, 2010, 164(2/3): 58-64.